What Does Plethora Solutions Do?

Total employees26
HeadquartersGuildford
Founded2003

Plethora Solutions PLC was a United Kingdom-based specialty pharmaceutical company primarily focused on the development and commercialization of treatments for urological disorders, with a significant emphasis on premature ejaculation (PE). Its flagship product was PSD502, a topical spray for PE, marketed under names such as Fortacin® and Senstend® in Europe. Founded in 2003, the company was listed on the AIM market of the London Stock Exchange. In late 2015 to early 2016, Plethora Solutions was acquired by Regent Pacific Group Limited, and its operations and assets, including the rights to Fortacin®, were integrated into the acquiring company. Plethora Solutions PLC was subsequently dissolved.

Where Is Plethora Solutions's Headquarters?

HQ Function

Served as a key center for research and development, clinical trial management, and strategic planning for its pharmaceutical products, notably PSD502.

Notable Features:

Located within The Surrey Research Park, a hub for technology and life science companies, offering access to specialized facilities and a collaborative environment. Specific internal features of Plethora's leased space are not publicly detailed.

Work Culture:

As a pharmaceutical R&D company, the culture likely prioritized scientific innovation, meticulous research, regulatory compliance, and a focus on bringing novel treatments to patients. This would have involved collaboration among scientists, clinicians, and business development professionals.

HQ Significance:

This operational base was crucial for advancing Plethora's lead product through clinical development, regulatory approval processes, and preparing for commercialization in European markets.

Values Reflected in HQ: The choice of a research park location underscored a commitment to scientific advancement, innovation, and being part of the UK's life sciences ecosystem.

Location:

Plethora Solutions' global presence was primarily driven by its efforts to secure regulatory approval and commercialize its lead product, Fortacin®/Senstend®, in Europe. While its operational core was in the UK, it established partnerships for distribution and marketing in various European countries post-product approval. It did not maintain a widespread network of international physical offices, instead leveraging licensing and distribution agreements to achieve market access outside the UK.

Street Address:

The Surrey Research Park (specific unit unconfirmed)

City:

Guildford

State/Province:

Surrey

Country:

United Kingdom

Where Else Does Plethora Solutions Operate Around the World?

Watford, Hertfordshire, UK

Address: Chancery House, 19 Degree C St. Albans Road, Watford, WD17 1DU, United Kingdom (Historical Registered Office)

Fulfilled UK legal requirements for company registration and official communications.

London, UK

Address: C/O Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES (Final Registered Office)

Served for final statutory requirements and legal processes during the company's dissolution.

Buying Intent Signals for Plethora Solutions

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Plethora Solutions? Meet the Executive Team

As of April 2025, Plethora Solutions' leadership includes:

James Barder - Chief Executive Officer
Mike Collini - Chief Financial Officer
Professor Michael G. Wyllie - Chief Scientific Officer
Ronald Openshaw - Non-Executive Chairman

Who's Investing in Plethora Solutions?

Plethora Solutions has been backed by several prominent investors over the years, including:

Regent Pacific Group Limited (also the eventual acquirer)
The Wellcome Trust
Invesco Asset Management
Henderson Global Investors
Various institutional and private shareholders (as an AIM-listed company)

What Leadership Changes Has Plethora Solutions Seen Recently?

Hire0
Exits0

Plethora Solutions PLC was acquired in 2015-2016 and subsequently dissolved. Therefore, there have been no executive new hires or exits for 'Plethora Solutions' as an independent entity in the last 12 months or for several years prior.

What Technology (Tech Stack) Is Used byPlethora Solutions?

Discover the tools Plethora Solutions uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Plethora Solutions Email Formats and Examples

Prior to its acquisition and dissolution, Plethora Solutions likely used a standard corporate email format. Common formats included [first].[last]@[companydomain].co.uk or [first_initial][last]@[companydomain].co.uk. These email addresses are no longer active.

[first].[last]@plethorasolutions.co.uk

Format

john.smith@plethorasolutions.co.uk (Example, Inactive)

Example

0%

Success rate

What's the Latest News About Plethora Solutions?

ReutersDecember 21, 2015

Plethora Solutions news title: Regent Pacific makes recommended offer for Plethora Solutions

Regent Pacific Group announced a recommended all-share offer to acquire Plethora Solutions PLC. The deal valued Plethora at approximately £102.7 million and was aimed at securing the rights to Plethora's premature ejaculation treatment, Fortacin....more

ZenopaNovember 14, 2013

Plethora Solutions news title: Plethora Solutions receives European approval for PSD502

Plethora Solutions announced that the European Commission had granted marketing authorisation for PSD502 (Fortacin™) for the treatment of premature ejaculation in the European Union, following a positive recommendation from the CHMP in September 2013....more

Pharmaceutical TechnologyMarch 8, 2010

Plethora Solutions news title: Plethora Solutions’ PSD502 Meets Phase III Endpoints

Plethora Solutions reported positive top-line results from its pivotal Phase III clinical trial for PSD502 (Tempe), its candidate treatment for premature ejaculation. The study met all primary and secondary endpoints, demonstrating a statistically significant improvement....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Plethora Solutions, are just a search away.